689 related articles for article (PubMed ID: 18665745)
1. Glioblastoma and stem cells.
Altaner C
Neoplasma; 2008; 55(5):369-74. PubMed ID: 18665745
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.
Piccirillo SG; Reynolds BA; Zanetti N; Lamorte G; Binda E; Broggi G; Brem H; Olivi A; Dimeco F; Vescovi AL
Nature; 2006 Dec; 444(7120):761-5. PubMed ID: 17151667
[TBL] [Abstract][Full Text] [Related]
3. Cancer: stem cells and brain tumours.
Dirks PB
Nature; 2006 Dec; 444(7120):687-8. PubMed ID: 17151644
[No Abstract] [Full Text] [Related]
4. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Bao S; Wu Q; McLendon RE; Hao Y; Shi Q; Hjelmeland AB; Dewhirst MW; Bigner DD; Rich JN
Nature; 2006 Dec; 444(7120):756-60. PubMed ID: 17051156
[TBL] [Abstract][Full Text] [Related]
5. Targeting brain-tumor stem cells.
Stupp R; Hegi ME
Nat Biotechnol; 2007 Feb; 25(2):193-4. PubMed ID: 17287755
[No Abstract] [Full Text] [Related]
6. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
7. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
8. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
11. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
12. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures.
Ropolo M; Daga A; Griffero F; Foresta M; Casartelli G; Zunino A; Poggi A; Cappelli E; Zona G; Spaziante R; Corte G; Frosina G
Mol Cancer Res; 2009 Mar; 7(3):383-92. PubMed ID: 19276180
[TBL] [Abstract][Full Text] [Related]
15. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
16. [Activation of CXCR4 in human glioma stem cells promotes tumor angiogenesis].
Ping YF; Yao XH; Bian XW; Chen JH; Zhang R; Yi L; Zhou ZH
Zhonghua Bing Li Xue Za Zhi; 2007 Mar; 36(3):179-83. PubMed ID: 17535685
[TBL] [Abstract][Full Text] [Related]
17. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
18. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties.
Tchoghandjian A; Baeza-Kallee N; Beclin C; Metellus P; Colin C; Ducray F; Adélaïde J; Rougon G; Figarella-Branger D
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S608-19. PubMed ID: 21989663
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
